1.215
Fate Therapeutics Inc Borsa (FATE) Ultime notizie
What drives Fate Therapeutics Inc. stock priceFree Market Dynamics Reports - Autocar Professional
How Fate Therapeutics Inc. stock performs during market volatilityHigh Accuracy Alerts - Newser
What analysts say about Fate Therapeutics Inc. stockSkyrocketing investment returns - jammulinksnews.com
Is Fate Therapeutics Inc. a good long term investmentExceptional gains - Autocar Professional
Fate Therapeutics Inc. Stock Analysis and ForecastLightning-fast capital gains - jammulinksnews.com
why fate therapeutics inc. stock attracts strong analyst attentionFree Day Trading Recommendations - Newser
what makes fate therapeutics inc. stock price move sharplyIntraday Trade Ideas - Newser
Fate Therapeutics, Inc. (FATE) Reaffirmed at Neutral After EULAR Data - MSN
Fate Therapeutics, Inc. (NASDAQ:FATE) Receives Average Rating of “Hold” from Brokerages - Defense World
Why Fate Therapeutics Inc. stock attracts strong analyst attentionFree Exclusive Investment Tips - Newser
What makes Fate Therapeutics Inc. stock price move sharplyFree Stock Selection - Newser
We Think Fate Therapeutics (NASDAQ:FATE) Needs To Drive Business Growth Carefully - Yahoo Finance
10 Best Get Rich Quick Stocks to Buy Now - Insider Monkey
Research Analysts Offer Predictions for FATE Q2 Earnings - Defense World
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Fate Therapeutics shares rise 3.57% after-hours after granting non-qualified stock options to a new employee. - AInvest
H.C. Wainwright maintains Neutral rating on Fate Therapeutics stock at $5 - Investing.com
Fate Therapeutics, Inc.(NasdaqGM: FATE) added to Russell Microcap Value Index - MarketScreener
Fate Therapeutics (NASDAQ:FATE) Downgraded to “Sell” Rating by Wall Street Zen - Defense World
Institutional owners may take dramatic actions as Fate Therapeutics, Inc.'s (NASDAQ:FATE) recent 20% drop adds to one-year losses - simplywall.st
Fate Therapeutics’ SWOT analysis: promising data boosts stock outlook - Investing.com
TC Biopharm (NASDAQ:TCBP) versus Fate Therapeutics (NASDAQ:FATE) Critical Review - Defense World
Fate Therapeutics (NASDAQ:FATE) Given “Hold” Rating at Needham & Company LLC - Defense World
FATE: Analyst Maintains Hold Rating on Fate Therapeutics | FATE Stock News - GuruFocus
Needham maintains hold on Fate Therapeutics stock despite lupus data By Investing.com - Investing.com Canada
Why Is Fate Therapeutics (FATE) Up 61.5% Since Last Earnings Report? - Yahoo Finance
Fate Therapeutics price target lowered to $2.20 by BofA on SLE data - Investing.com Canada
Fate Therapeutics (FATE) Shares Promising Data on FT819 for Lupus Treatment | FATE Stock News - GuruFocus
Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress - The Manila Times
Fate Therapeutics Reports Promising Clinical Data for FT819 in Treating Severe Lupus Nephritis at EULAR 2025 - Nasdaq
Fate’s FT819 shows promising results in lupus patients - Investing.com
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):